Immunic (IMUX) Interest Expenses (2013 - 2026)

Immunic (IMUX) has 14 years of Interest Expenses data on file, last reported at $3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 19923.16% year-over-year to $3.3 million; the trailing twelve-month figure through Mar 2026 stood at $3.3 million (up 19923.16% YoY), and the FY2025 full-year result was $119.9 million, up 2.39% from the prior year.
• Interest Expenses climbed to $3.3 million in Q1 2026, from $207000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $73.1 million in Q4 2022 to a low of $1875.0 in Q2 2024.
• A 5-year average of $5.1 million and a median of $207000.0 in 2025 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses plunged 99.91% in 2024 and soared 19923.16% in 2026, its largest moves.
• Tracing IMUX's Interest Expenses over 5 years: stood at $73.1 million in 2022, then tumbled by 98.61% to $1.0 million in 2023, then sank by 96.25% to $38000.0 in 2024, then surged by 444.74% to $207000.0 in 2025, then soared by 1509.11% to $3.3 million in 2026.
• Business Quant data shows IMUX's Interest Expenses at $3.3 million in Q1 2026, $207000.0 in Q4 2025, and $1.1 million in Q3 2025.